UCB Reports Positive Results from Phase 3 Study of Zilucoplan in Myasthenia Gravis globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.
UCB, maker of several epilepsy drugs, is expanding its portfolio in the field with an acquisition. For up to $1.9 billion, the Belgian pharma has agreed to buy Zogenix, developer of blockbuster hopeful Fintepla.
/PRNewswire/ 1:30 p.m. ET: UCB today announced that new data from its seizure treatment portfolio (BRIVIACT, NAYZILAM, and VIMPAT) will be showcased at the.
/PRNewswire/ 1:30 p.m. ET: UCB today announced that new data from its seizure treatment portfolio (BRIVIACT, NAYZILAM, and VIMPAT) will be showcased at the.